Skip to main content

Table 4 Longitudinal outcomes in YMRS and HAM-D: monotherapy versus aggregated combination therapies

From: A pilot trial of quetiapine, lithium, or placebo added to divalproex sodium for hypomanic or manic episodes in ambulatory adults with bipolar I disorder

Predictors

YMRS

HAM-D

Estimates

CI

p

Estimates

CI

p

Group [combination]

0.39

− 2.69–3.47

0.802

1.41

− 1.32–4.15

0.307

Time [days]

− 0.13

− 0.17 to − 0.08

< 0.001***

− 0.05

− 0.09 to − 0.02

0.005**

Site [VA]

0.37

− 3.34–4.07

0.844

− 4.59

− 8.08 to − 1.11

0.011*

Group [combination] × time

− 0.02

− 0.08–0.04

0.443

0.02

− 0.03–0.07

0.359

  1. Monotherapy: divalproex plus placebo; combination: combination therapy of divalproex plus blinded lithium and divalproex plus blinded quetiapine
  2. VA Palo Alto
  3. *p < 0.05, **p < 0.01, ***p < 0.001